世界の糖尿病および糖尿病合併症治療市場動向：第3版

Abstract

The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just 3 years ago. New trends in care, new products (both therapeutic and diagnostic), new approaches to long-term complications, and changing public health priorities and geographic variations are shifting the sands of opportunities in diabetes care.

This comprehensive re-evaluation of the major world market for diabetes monitoring and therapeutic products provides in-depth data and analysis including:

• Detailed epidemiology by country of Type I and II diabetes, with forecasts through 2016
• Market size and growth for each segment and subsegment in each country through 2016
• Thorough discussions of products on the market and evaluations of new products and technologies in development that may change the market of the future
• Considerations of the geographic market variations and very different diabetes care environments to be found in each of the major national markets.
• In-depth profiles of the top competitors and their diabetes-related portfolios
• 17 conclusions and strategic implications competitors in the marketplace must take into account as they formulate future plans

Market data (including size and growth projections) are provided for the major diagnostic and therapeutic segments:

• Glucose monitoring
• Insulin
• Oral hypoglycemics
• Antihypertensives for diabetes-related hypertension
• Lipid-lowering drugs for diabetes-related dyslipidemia
• Antiarrhythmics for diabetes-related arrhythmias
• Various drugs for diabetes-related peripheral vascular disease

The major world markets covered in the study include:

• France
• Germany
• Italy
• Japan
• Spain
• United Kingdom
• United States

The analysis presented in this report is based on data from a combination of company, government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including diabetologists, endocrinologists, internists, pathologists, research scientists, business development managers and marketing managers.

Table of Contents

chapter one: Executive Summary

• Background
• Scope and Methodology
• Size and Growth of Market
• The Nature of the Industry
• The New Technologies
• Market Trends

chapter two: Introduction

• Background
• The Pathology of Diabetes and Its Complications
  • Diabetes
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Long-Term Complications of Diabetes
  • Hypertension
  • Dyslipidemia
  • Cardiovascular Disease
  • Vascular Complications
  • Diabetic Retinopathy
  • Renal Complications
  • Neuropathies
  • Diabetic Foot
• Epidemiology
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom
  • United States

chapter three: Diabetes Monitoring

• Background
• Glucose Monitoring
  • Background and History
  • Urine Testing
  • Blood Testing
  • Colorimetric Monitors
  • Modern Glucose Monitors
  • Leading Products
  • Features and Marketing Approach
  • Noninvasive Techniques
  • Near Infrared (NIR) Spectroscopy
  • Mid-Infrared Absorption/Emission
  • Stimulated Emissions (Raman or Fluorescence)
  • Terahertz Spectroscopy
  • Photoacoustic Spectroscopy
  • Optical Rotation
  • Optical Rotation in Tissue
  • Light Scattering
  • Transdermal Techniques (Trans-Membrane) Techniques
  • Subdermal Techniques
• Hemoglobin A1C (HbA1C)
  • Background
  • Standardization Issues
  • Levels and Goals
  • Products
• Ketone Monitoring
• Microalbumin Monitoring

chapter four: Current Therapeutic Approaches

• Background
• Therapeutic Practices
  • France
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Germany
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Italy
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Japan
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • Spain
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • United Kingdom
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
  • United States
    • Diabetes
    • Complication: Hypertension
    • Complication: Dyslipidemia
    • Complication: Atherosclerosis
    • Complication: Arrhythmias
    • Complication: Peripheral Vascular Disease
• Current Therapeutics for Diabetes
  • Insulin
    • Regular Insulin
    • Long-Acting and Basal Insulin
    • Rapidly Acting Insulin
    • Combinations
    • Insulin Pumps
    • Insulin Pens
    • Inhaled Insulin
    • Other Treatments
  • Oral Hypoglycemics
    • Sulfonylureas
    • Biguanides
    • á-Glucosidase Inhibitors
    • Thiazolidinediones
    • Meglitinides
    • D-Phenylalanine Derivatives
    • Peptide Amides
  • Current Therapeutics for Diabetic Complications
    • Antihypertensive Therapy
      • ACE Inhibitors
      • á/â(Alpha/Beta)-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Angiotensin II Receptor Antagonists
    • Dyslipidemia Therapy
      • HMG-CoA Reductase Inhibitors--Statins
      • Bile Acid Sequestrants
      • Fibric Acid Derivatives
      • Niacin
      • Cholesterol Absorption Inhibitors
    • Atherosclerosis Therapy
    • Arrhythmia Therapy
    • Peripheral Vascular Disease Therapy

Chapter five: Diabetes Monitoring and Therapeutics Markets

• Background
• Market Status and Segmentation
  • Diabetes Monitoring
  • Blood Ketones
  • Microalbumin
  • Blood Glucose
  • Geographic Variation
• Therapeutics
  • Insulin
  • Oral Hypoglycemics
  • Diabetic Complication Drugs
• Market Trends in Geographic Markets
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom
  • United States

chapter six: Nutritional Supplement and Herbal Approaches to the Treatment of Diabetes

• Background
• Nutritional Supplements
  • Ascorbic Acid (Vitamin C)
  • Biotin
  • Chromium
  • Copper
  • Magnesium
  • Niacin and Niacinamide
  • Potassium
  • Selenium
  • Thiamine
  • Vanadium
  • Vitamin B6 (Pyridoxine)
  • Vitamin B12
  • Vitamin E
  • Zinc
  • Nutritional Treatment of Diabetic Neuropathy
• Herbal Treatment of Diabetes
  • Aloe (Various)
  • Arctium lappa (Burdock Root)
  • Allium cepa (Onion)
  • Grifola frondosa (Maitake Mushroom)
  • Mulberry
  • Panax ginseng (Korean ginseng)
• Ayurvedic Medicine and Herbs
  • Gymnema sylvestre (Asclepias germinata)
  • Momordica charantia (Bitter Gourd)
  • Trigonella foenum graecum (Fenugreek)
• Other Herbs with Significant Anti-Diabetic Effects
• Traditional Chinese Medicine

chapter seven: Forward Looking Technologies

• New Products and the Development Pipeline
• â-Cell Transplantation Research

chapter eight: Company Profiles

• Abbott Laboratories
• Amylin Pharmaceuticals
• AstraZeneca
• Bayer Healthcare Diabetes Care
• GlaxoSmithKline
• Eli Lilly & Co.
• Metabolex, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi-Aventis US

chapter nine: Conclusions and Strategic Implications

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:
• Eighth Conclusion
• Implications:
• Ninth Conclusion
• Implications:
• Tenth Conclusion
• Implications:
• Eleventh Conclusion
• Implications:
• Twelfth Conclusion
• Implications:
• Thirteenth Conclusion
• Implications:
• Fifteenth Conclusion
• Implications:
• Sixteenth Conclusion
• Implications:
• Seventeenth Conclusion
• Implications:

Appendix A:GLOSSARY

Appendix B: Company Directory

List of Exhibits

chapter one: Executive Summary

• Figure 1-1: Diagnosed Diabetes Cases in the Seven Major World Healthcare Markets: 2004 - 2014
• Figure 1-2: Trending in the Market Potential in the World' s Major Blood Glucose Monitoring Markets 2006 - 2016
• Table 1-1: Estimated Market Potential for Insulin in the Seven Major World Healthcare Markets 2006 - 2016
• Table 1-2: Estimated Market Potential for Oral Hypoglycemics in the Seven Major World Healthcare Markets 2006 - 2016
• Table 1-3: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets by Complication (Hypertension, Dyslipidemia, Arrhythmias, Peripheral Vascular Disease) 2006 - 2016

chapter two: Introduction

• Table 2-1: Characteristics of Type I and Type II Diabetes Mellitus
• Table 2-2: Common Symptoms and Conditions of Diabetes Mellitus
• Table 2-3: Populations of Each of the Seven Major Healthcare Markets 2006-2016
• Table 2-4: Populations of Each of the Seven Major World Healthcare Markets by Age Group (0-14, 15-64, 65+ Years) 2006
• Table 2-5: Prevalence Rates and Cases for Diabetes Mellitus by Type (Type I vs Type II) in Each of the Seven Major World Healthcare Markets 2006
• Table 2-6: Prevalence of Diabetes in the Seven Major World Healthcare Markets by Type (I vs II) 2004-2014
• Figure 2-1: Trending in the Total Prevalence of Diabetes Cases and the General Population in the Seven Major World Healthcare Markets 2006 - 2016
• Figure 2-2: Composition of the Diabetes Patient Population in the Seven Major World Healthcare Markets 2006-2016
• Figure 2-3: Geographic Distribution of the Total Diabetes Patient Population 2006 and 2016
• Figure 2-4: Geographic Distribution of the Type 1 Diabetes Patient Population 2006 and 2016
• Figure 2-5: Geographic Distribution of the Type 2 Diabetes Patient Population 2006 and 2016
• Figure 2-6: Population Trends in the Seven Major World Healthcare Markets: 2006-2016
• Figure 2-7: The Prevalence of Diabetes in France: 2006 - 2016
• Figure 2-8: The Prevalence of Diabetes in Germany: 2006 - 2016
• Figure 2-9: The Prevalence of Diabetes in Italy: 2006 - 2016
• Figure 2-10: The Prevalence of Diabetes in Japan: 2006 - 2016
• Figure 2-11: The Prevalence of Diabetes in Spain: 2006 - 2016
• Figure 2-12: The Prevalence of Diabetes in the United Kingdom: 2006 - 2016
• Figure 2-13: The Prevalence of Diabetes in the United States: 2006 - 2016

chapter three: Diabetes Monitoring

• Table 3-1: Key Glucose Monitoring Products on the Market
• Table 3-2: Twenty-Five Year Historic Record of Glucose Monitors Approved by the U.S. Food and Drug Administration (Product, Company, Approval Date)
• Table 3-3: Key HbA1C Monitors and Test Kit Services (Company, Product, Description)
• Table 3-4: Key Ketone Monitoring Products on the Market (Company, Product, Description)
• Table 3-5: Key Microalbumin Monitoring Products on the Market (Company, Product, Description)

chapter four: Current Therapeutic Approaches

• Table 4-1: Estimated Number of Preventable Diabetes Cases and Complications in the United States
• Table 4-2: Key Insulin Products for the Treatment of Diabetes (Brand, Insulin Type, Manufactuer/Marketer)
• Table 4-3: Key Oral Hypoglycemics for the Treatment of Type II Diabetes (Brand, Compound, Manufacturer/Marketer, Class)
• Table 4-4: Common ACE Inhibitors on the Market for Diabetic Hypertension (Brand, Compound, Manufacturer/Marketer)
• Table 4-5: Common Adrenergic Receptors (á and â) on the Market for Diabetic Hypertension (Brand Name, Compound, Manufacturer/ Marketer, Receptor Type)
• Table 4-6: Common Calcium Channel Blockers and Combinations on the Market for Diabetic Hypertension (Brand Name, Compound, Manufacturer/Marketer)
• Table 4-7: Common Diuretic Products and Diuretic Combinations on the Market for Diabetic Hypertension (Brand, Compounds, Manufacturer/Marketer, Class)
• Table 4-8: Common Angiotensin II Receptor Antagonists on the Market for Diabetic Hypertension ((Brand, Compound, Manufacturer/ Marketer)
• Table 4-9: Commonly Used Antilipemic Agents on the Market for Diabetic Dyslipidemia (Brand, Compounds, Manufacturer/Marketer, Class)
• Table 4-10: Vaughn Williams Classification of Anti-Arrhythmic Drugs
• Table 4-11: Common Antiarrhythmatic Drugs (Brand, Compound, Manufacturer/Marketer, Group)
• Table 4-12: Drugs Commonly Used to Combat Diabetic Peripheral Vascular Disease (Brand, Compound, Manufacturer/Marketer, Type)

Chapter five: Diabetes Monitoring and Therapeutics Markets

• Table 5-1: Estimated Market Sizes for Blood Glucose Monitoring Equipment and Supplies in the Seven Major World Healthcare Markets by Country 2006-2016
• Figure 5-1: Trending in the World' s Major Blood Glucose Monitoring Markets (Total): 2006 - 2016
• Figure 5-2: Distribution of the World' s Major Blood Glucose Monitoring Markets by Country: 2006 / 2011 / 20016
• Figure 5-3: Estimated Market Shares of the Key Participants in the Seven Major World' s Markets for Glucose Monitoring Products: 2006
• Table 5-2: Estimated Market Sizes for Insulin in the Seven Major World Healthcare Markets by Country 2006 - 2016
• Figure 5-4: Trending in the World' s Major Markets for Insulin: 2006 - 2016
• Figure 5-5: Market Distribution in the World' s Major Markets for Insulin 2006 - 2016
• Figure 5-6: Estimated Insulin Market Shares in the Seven Major World Healthcare Markets: 2006
• Table 5-3: Estimated Market Sizes for Oral Hypoglycemics in the Seven Major World Healthcare Markets by Country 2006 - 2016
• Figure 5-7: Trending in the World' s Major Markets for Oral Hypoglycemic Drugs: 2006 - 2016
• Figure 5-8: Market Distribution in the World' s Major Markets for Oral Hypoglycemics: 2006 - 2016
• Figure 5-9: Estimated Oral Hypoglycemic Drug Market Shares in the Seven Major World Healthcare Markets: 2006
• Table 5-4: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets by Drug Type (Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmia Drugs, Peripheral Vascular Disease Drugs) 2016-2016
• Figure 5-10: Trending in the Total World' s Major Markets for Drugs to Treat Diabetic Complications (By Complication): 2006 - 2016
• Figure 5-11: Composition of the Total World' s Major Markets for Drugs to Treat Diabetic Complications (by Complication): 2006 - 2016
• Table 5-5: Estimated Diabetes-Care Market Size in France by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2006 - 2016
• Figure 5-12: Trending in the French Market for Diabetes-Care Products Product Class: 2006 - 2016
• Figure 5-13: Composition of the French Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-6: Estimated Diabetes-Care Market Size in Germany: by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs) 2006 - 2016
• Figure 5-14: Trending in the German Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-15: Composition of the German Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-7: Estimated Diabetes-Care Market Size in Italy by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-16: Trending in the Italian Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-17: Composition of the Italian Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-8: Estimated Diabetes-Care Market Size in Japan by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-18: Trending in the Japanese Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-19: Composition of the Japanese Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-9: Estimated Diabetes-Care Market Size in Spain: by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-20: Trending in the Spanish Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-21: Composition of the Spanish Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-10: Estimated Diabetes-Care Market Size in the United Kingdom by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-22: Trending in the United Kingdom Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-23: Composition of the United Kingdom Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Table 5-11: Estimated Diabetes-Care Market Size in the United States: by Segment (Blood Glucose Monitoring, Insulin, Oral Hypoglycemics, Antihypertensives, Lipid-Lowering Drugs, Antiarrhythmics, and Peripheral Vascular Disease Drugs), 2006 - 2016
• Figure 5-24: Trending in the United States Market for Diabetes-Care Products by Product Class: 2006 - 2016
• Figure 5-25: Composition of the United States Market for Diabetes-Care Products by Product Class: 2006 - 2016

chapter seven: Forward Looking Technologies

• Table 7-1: Recently Introduced or Diabetes-Designated Products (Product, Generic Name, Company, Diabetes Type, Introduction/Approval Date)
• Table 7-2: Products in Development for Diabetes and Diabetic Complications (Brand Name, Generic Name, Indications, Company, Development Status)